GlassScriptPhysician profile
Ivania M Rizo
NPI 1073753414
$22,458.78
in general payments reported to CMS, 2019-2025
5 companies · $8,231 in 2025
The $8,231 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.95 · 2020: $112 · 2022: $126 · 2023: $279 · 2024: $14K · 2025: $8,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Travel and Lodging: $3,691 · Food and Beverage: $872 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,580.00 |
| Travel and Lodging | $3,690.74 |
| Food and Beverage | $872.48 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $16,761.89 | 2019-2025 | Rybelsus |
| Genentech, INC. | $5,331.03 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $161.37 | 2022-2023 | Imcivree |
| Tandem Diabetes Care, INC. | $112.38 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $92.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivania Rizo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.